Power Law company profile

Human Immunology Biosciences

Biotech & Life Sciences · San Francisco, United States · Founded 2021 Unicorn

Biotechnology company focused on developing therapies for immune-mediated diseases

Valuation

$1–2.5B

Latest valuation · 2026

Unlock exact value

Headcount

<100

Current team size

Unlock exact value

Featured in Unicorn$1B+ valuation tier · Power Law dataset 2026

Investors

6 investors on Human Immunology Biosciences's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Series A 3 investors entered at this stage

Monograph Capital

ARCH Venture Partners

Jeito Capital

Series B+ 3 investors entered at this stage

Arkin Capital

Alpha Wave Global

Viking Global Investors

Global footprint

Where Human Immunology Biosciences has talent and traffic

Workforce by country

2 countries with
team presence

🇺🇸 United States95%

🇦🇺 Australia5%

2 countries shown

Web traffic by country

670 monthly visits
across markets

🇺🇸 United States104.5%

Top 1 markets shown

Market sentiment

What the market is saying about Human Immunology Biosciences

An AI-synthesized read of the highest-engagement posts about Human Immunology Biosciences on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Human Immunology Biosciences on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Book a demo Explore company profiles